[POSSIBLE DRUG CORRECTION OF LIPID METABOLISM DISTURBANCES ASSOCIATED WITH METABOLIC SYNDROME IN PATIENTS WITH PSORIASIS].
Dontsova. E V EV
Key Findings
- Semax added to standard therapy reduced total cholesterol, triglycerides, and LDL levels
- Semax increased HDL levels
- Standard therapy without semax showed no significant lipid changes
Practical Outcomes
- For biohackers interested in lipid health, a brief intranasal semax regimen may help improve cholesterol profiles, especially in those with metabolic syndrome, but the study is limited to psoriasis patients and the exact dosing is unclear, so start cautiously and monitor blood lipids.
Summary
A short 10‑day course of intranasal semax (0.1% solution, about 600 mg per day) added to regular psoriasis treatment lowered bad cholesterol, triglycerides and LDL, while raising good HDL in patients who also had metabolic syndrome. The usual treatment alone didn’t change these blood fats.
Abstract
It was studied the possibility of correcting lipid metabolism in patients with psoriasis and concomitant metabolic syndrome (MS) by using additional treatment with semax. In group 1, 58 patients received conventional therapy, while 60 patients in group 2 received the same with additional 0.1% semax solution intranasally 600 mg/day for 10 days. It was found that the inclusion of semax in complex treatment of patients with psoriasis complicated by metabolic syndrome led to a decrease in the initially elevated serum levels of total cholesterol, triglycerides, LDL cholesterol and to an increase in the initially reduced levels of HDL cholesterol, in contrast to the standard treatment, which did not produce any statistically significant effect on the levels of total cholesterol, triglycerides, LDL cholesterol, and HDL cholesterol in the blood serum.
Study Information
pubmed
2015